A WeChat-delivered Information-Motivation-Behavioral skills intervention to improve HPV vaccine acceptability among Chinese gay, bisexual, and other men who have sex with men

一项通过微信传播的信息-动机-行为技能干预措施,旨在提高中国男同性恋、双性恋及其他男男性行为者对HPV疫苗的接受度。

阅读:4

Abstract

Culturally appropriate strategies are urgently needed to promote human papillomavirus (HPV) vaccination among Chinese gay, bisexual, and other men who have sex with men. WeChat-based interventions guided by the Information - Motivation - Behavioral Skills (IMB) model offer a theory-driven approach by targeting knowledge, motivation, social norms, and self-efficacy. To evaluate a WeChat-delivered IMB-based intervention designed to improve HPV vaccine acceptability in this population. HPV vaccine acceptability and IMB constructs were assessed at baseline (T(0)), immediately post-intervention (T(1)), and 1 month post-intervention (T(2)). Intervention effects were estimated using generalized estimating equations. Mediation was examined using Hayes' PROCESS macro (Model 4) based on change scores with bootstrapped confidence intervals (CIs). The intervention group reported significantly higher HPV vaccine acceptability at T(1) (β = 0.42, 95% CI [0.17, 0.68]; p < .001), although effects attenuated at T(2) (β = 0.28, 95% CI [0.00, 0.56]; p = .05). Within the intervention group, mean acceptability increased from 3.31 at T(0) to 3.86 at T(1), representing a 16.6% increase. Significant improvements were also observed at T(1) in HPV knowledge, perceived severity, perceived effectiveness, anticipated regret, subjective norms, and self-efficacy, with partial declines observed at T(2). Mediation analyses identified knowledge (β = 0.357, 95% CI [0.228, 0.487]), subjective norms (β = 0.356, 95% CI [0.288, 0.425]), and self-efficacy (β = 0.324, 95% CI [0.244, 0.405]) as key mediators of intervention effects. WeChat-delivered IMB intervention improved short-term HPV vaccine acceptability. Sustaining these effects will require additional strategies to ensure long-term sustainability.Clinical Trial Registration: ChiCTR2400089627.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。